DEVELOPMENT OF NOVEL THERAPIES FOR NIDDM

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。重组腺病毒是一种传递基因的工具，可以调节糖尿病动物模型中肝脏葡萄糖处理和产生之间的平衡，从而深入了解该疾病中肝功能障碍的机制以及新的治疗策略。近年来，这项工作的重点是糖原家族靶向蛋白磷酸酶-1 （PP-1）亚基。这些蛋白作为将PP-1与其底物糖原磷酸化酶、糖原合成酶和磷酸化酶激酶并置的支架。早期与罗杰斯中心的合作研究使用13C核磁共振证明腺病毒介导的靶亚基家族成员PTG的表达通过间接（糖异生）途径刺激糖原合成。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant adenoviruses are a tool for delivery of genes that can modulate the balance between hepatic glucose disposal and production in animal models of diabetes, thereby gaining insights into mechanisms of hepatic dysfunction in the disease as well as novel therapeutic strategies. In recent years this work has focused on a family of glycogen targeting subunits of protein phosphatase-1 (PP-1). The proteins serve as scaffolds for juxtaposing PP-1 with its substrates glycogen phosphorylase, glycogen synthase, and phosphorylase kinase. Early collaborative studies with the Rogers Center used 13C NMR to demonstrate that adenovirus-mediated expression of PTG, a targeting subunit family member, stimulates glycogen synthesis by the indirect (gluconeogenic) pathway.